The Medical Device GMP Regulations published in February 2026 introduce important updates to the Korean Good Manufacturing Practice (KGMP) framework overseen by the Ministry of Food and Drug Safety (MFDS).
The revised requirements strengthen manufacturing oversight, enhance inspection expectations, and clarify documentation standards for both domestic and foreign manufacturers seeking access to the Korean medical device market.
Korea remains one of the most strictly regulated markets in Asia, and KGMP certification continues to be a mandatory prerequisite for product approval and market entry. The 2026 updates further align Korean GMP with international standards such as ISO 13485, while maintaining country-specific compliance obligations.
KGMP certification requirements for foreign manufacturers
One of the most critical aspects of Korean Medical Device GMP compliance concerns foreign manufacturers exporting devices to Korea. Unlike some jurisdictions that rely primarily on ISO 13485 certification, Korea requires formal KGMP certification issued under MFDS supervision.
The updated 2026 regulations reinforce that foreign manufacturers must demonstrate:
- full implementation of a compliant quality management system,
- documented process validation for critical manufacturing stages,
- traceability of components and materials,
- defined responsibilities for quality control and quality assurance,
- structured change management procedures.
In addition, Korean importers play a central regulatory role and are expected to ensure ongoing compliance with KGMP requirements, including maintaining communication with the foreign manufacturer and supporting inspection readiness.
MFDS GMP inspections – increased scrutiny and documentation standards
The 2026 regulatory update places greater emphasis on MFDS inspection procedures. On-site inspections remain a key component of KGMP certification, particularly for higher-risk devices.
The updated framework highlights:
- enhanced review of sterilisation validation records,
- stricter expectations for environmental monitoring in controlled areas,
- deeper assessment of supplier qualification systems,
- verification of complaint handling and corrective action processes.
For implantable and higher-class devices, MFDS may conduct more detailed audits focusing on risk management integration within manufacturing controls.
The inspection process evaluates not only compliance with documented procedures but also the effectiveness of implementation. Manufacturers must therefore ensure that operational practice aligns fully with documented QMS processes.
Integration of KGMP and Post-Market Surveillance in Korea
A significant development under Korean Medical Device GMP 2026 is the stronger linkage between manufacturing controls and post-market obligations.
MFDS expects manufacturers to demonstrate that:
- complaint data is systematically analysed,
- trend analysis informs production adjustments,
- corrective and preventive actions (CAPA) are effectively implemented,
- safety information is communicated to Korean importers and authorities when required.
This integration reflects a lifecycle approach to device regulation. Manufacturing quality is no longer assessed independently of market performance data.
For companies already operating under EU MDR or US FDA frameworks, the conceptual alignment will be familiar. However, Korea’s documentation depth and inspection focus remain distinct and often more formalised.
Change control and supplier management under KGMP 2026
The updated KGMP framework reinforces strict control over manufacturing changes. Any modification affecting:
- raw materials,
- critical suppliers,
- production equipment,
- software systems controlling manufacturing processes,
must undergo documented risk assessment and approval prior to implementation.
Supplier qualification systems must include regular evaluation, defined quality agreements, and performance monitoring. MFDS inspections increasingly review supplier oversight as a core compliance area.
Manufacturers relying on complex international supply chains should anticipate additional scrutiny in this area.
Strategic implications for Korea medical device market access
For companies seeking entry into the Korean medical device market in 2026 and beyond, KGMP certification should be treated as a strategic project rather than an administrative requirement.
The updated regulations confirm that:
- ISO 13485 certification alone is insufficient for Korea,
- documentation must be prepared specifically to meet MFDS expectations,
- inspection readiness must be continuously maintained, not only prepared shortly before audit.
Manufacturers of Class III and implantable devices should allocate additional resources to validation documentation, risk management integration, and inspection simulations.
Early gap assessments against the updated KGMP requirements can significantly reduce delays during MFDS review and inspection.
Korean medical device GMP 2026 – preparing for MFDS compliance
To ensure successful KGMP certification under the 2026 framework, manufacturers should:
- conduct a structured KGMP gap analysis,
- review process validation documentation,
- strengthen supplier qualification records,
- integrate PMS feedback loops into manufacturing oversight,
- align technical documentation with Korean regulatory expectations.
Korea continues to position itself as a highly regulated but commercially attractive market. The updated KGMP rules reinforce that regulatory preparedness and quality maturity are decisive competitive advantages.
For international manufacturers, early adaptation to Korean Medical Device GMP 2026 will be essential to secure uninterrupted access to one of Asia’s most important medical technology markets.